

RESEARCH ARTICLE

Soluble CD163 Changes Indicate Monocyte Association With Cognitive Deficits in Parkinson's Disease

Sara Konstantin Nissen, PhD,¹  Sara Almeida Ferreira, MSc,¹ Marlene Christina Nielsen, PhD,² Claudia Schulte, MSc,³  Kalpana Shrivastava, PhD,¹ Dorle Hennig, PhD,⁴ Anders Etzerodt, PhD,¹ Jonas Heilskov Graversen, PhD,⁴ Daniela Berg, MD,^{3,5} Walter Maetzler, MD,⁵ Anne Panhelainen, PhD,⁶ Holger Jon Møller, MD, PhD,² Kathrin Brockmann, MD,³ and Marina Romero-Ramos, PhD^{1*} 

¹DANDRITE and Department of Biomedicine, Aarhus University, Aarhus, Denmark

²Department of Clinical Biochemistry, Aarhus University Hospital, Aarhus, Denmark

³Center of Neurology, Department of Neurodegeneration and Hertie-Institute for Clinical Brain Research & German Center for Neurodegenerative Diseases, University of Tuebingen, Tuebingen, Germany

⁴Department of Molecular Medicine, University of Southern Denmark, Odense, Denmark

⁵Department of Neurology, Christian-Albrechts University, Kiel, Germany

⁶Institute of Biotechnology, University of Helsinki, Helsinki, Finland

ABSTRACT: Background: Parkinson's disease (PD) is a neurodegenerative disorder with a significant immune component, as demonstrated by changes in immune biomarkers in patients' biofluids. However, which specific cells are responsible for those changes is unclear because most immune biomarkers can be produced by various cell types.

Objectives: The aim of this study was to explore monocyte involvement in PD.

Methods: We investigated the monocyte-specific biomarker sCD163, the soluble form of the receptor CD163, in cerebrospinal fluid (CSF) and serum in two experiments, and compared it with other biomarkers and clinical data. Potential connections between CD163 and alpha-synuclein were studied *in vitro*.

Results: CSF-sCD163 increased in late-stage PD and correlated with the PD biomarkers alpha-synuclein, Tau, and phosphorylated Tau, whereas it inversely correlated with the patients' cognitive scores, supporting monocyte involvement in neurodegeneration and cognition in PD. Serum-sCD163 increased only in female patients, suggesting a sex-distinctive monocyte response. CSF-

sCD163 also correlated with molecules associated with adaptive and innate immune system activation and with immune cell recruitment to the brain. Serum-sCD163 correlated with proinflammatory cytokines and acute-phase proteins, suggesting a relation to chronic systemic inflammation. Our *in vitro* study showed that alpha-synuclein activates macrophages and induces shedding of sCD163, which in turn enhances alpha-synuclein uptake by myeloid cells, potentially participating in its clearance.

Conclusions: Our data present sCD163 as a potential cognition-related biomarker in PD and suggest a role for monocytes in both peripheral and brain immune responses. This may be directly related to alpha-synuclein's proinflammatory capacity but could also have consequences for alpha-synuclein processing. © 2020 The Authors. *Movement Disorders* published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society

Key Words: alpha-synuclein; biomarkers; cognition; monocytes; sCD163

This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

*Correspondence to: Prof. Marina Romero-Ramos, Department of Biomedicine, Aarhus University, Høegh-Guldbergsgade 10, DK-8000 Aarhus C, Denmark; E-mail: mrr@biomed.au.dk

Relevant conflicts of interest/financial disclosures: Nothing to report. Full financial disclosures and author roles may be found in the online version of this article.

Funding agencies: Funding support for the research covered by this article was provided by the Michael J. Fox Foundation (M.R.-R.), the Bjarne

Saxhof Fund administered through the Danish Parkinson's Foundation (M.R.-R.), the Aarhus University Research Foundation, AU IDEAS center NEURODIN (M.R.-R.), and the Novo Nordisk Foundation (DEO, NNF17OC0028806). S.A.F. is supported by a PhD fellowship from the PhD School at the Health Faculty, Aarhus University.

Received: 13 May 2020; **Revised:** 12 November 2020; **Accepted:** 13 November 2020

Published online 17 December 2020 in Wiley Online Library (wileyonlinelibrary.com). DOI: 10.1002/mds.28424

Parkinson's disease (PD) is characterized by intraneuronal aggregations of alpha-synuclein (α -syn) and dopaminergic neuronal death in the midbrain. PD also involves early and chronic immune activation,¹ where α -syn acts as a damage-associated molecular pattern, initiating inflammation and promoting disease.² The immune response involves microglia in the brain and blood immune cells, such as monocytes/macrophages and lymphocytes. In patients with PD, the monocytic population shows increased proliferative and phagocytic capacity, abnormal response to immune stimuli,^{3,4} and an altered transcriptome.⁵ PD-derived T cells show a bias toward proinflammatory Th1/Th17 phenotypes.^{6,7} Accordingly, the PD immune response involves both innate and adaptive immune components. These peripheral alterations will affect the central nervous system (CNS) because T cells and monocytes infiltrate the brain in patients with PD and PD models.⁸⁻¹⁰ This results in changes in cytokines and chemokines in patients' serum and cerebrospinal fluid (CSF). A recent meta-analysis reports increased interleukin (IL)-1 β , tumor necrosis factor- α (TNF- α), IL-6, and IL-10 in the blood of patients with PD, whereas in CSF, IL-1 β , IL-6, transforming growth factor (TGF)- β 1, and C-reactive protein (CRP) are elevated.¹¹ These biomarkers correlate with PD symptomatology,¹ further supporting their disease relevance.

These PD-related immune biomarkers can be produced by multiple cell types¹² and cannot truly reveal the unique intervention of each cell population involved in the PD immune response. Conversely, this is not the case with soluble CD163 (sCD163), a well-characterized protein produced exclusively by the monocyte cell lineage, but not by lymphocytes, neurons,^{13,14} or microglia, as confirmed recently by single-cell RNA analysis.¹⁵⁻¹⁷ In the brain, CD163 is expressed only by non-microglia CNS myeloid cells, such as meningeal and perivascular macrophages.¹⁷⁻¹⁹ sCD163 is constitutively produced in serum and CSF²⁰ upon immune signals, through mechanisms similar to that releasing TNF- α during inflammatory processes.^{21,22} Therefore, increased sCD163 levels in biofluids relate to macrophage activation and correlate with the degree of inflammation.¹⁴ In this study, we analyze sCD163 levels in serum and CSF from patients with early and late PD to evaluate monocytic activation in different PD stages.

Patients and Methods

Study Participants

Patients with PD were recruited from the outpatient clinic and/or ward for PD, University Hospital of Tuebingen, Germany. Healthy control subjects (HCs) were assessed as having no neurodegenerative disease. All participants were examined by a neurologist

specialized in movement disorders. A PD diagnosis was made according to the UK Brain Bank Society Criteria.²³ Serum and CSF were collected and stored at the Neuro-Biobank, University of Tuebingen and sent for experimental work at Aarhus University, Denmark (see Supporting Information). The study was approved by the local ethics committee (480/2015BO2), with all participants providing informed consent.

This cross-sectional study included serum and CSF from patients with idiopathic PD [early (<5 years) and late ($\geq$ 5 years from diagnosis)] and HCs (Supporting Information Fig. S1). Samples were received and analyzed in two separate experiments with a 2-year separation: Exp#1 included 109 patients with PD and 44 HCs (Supporting Information Table S1), and Exp#2 included 106 patients with PD and 16 HCs (Supporting Information Table S2). Twenty-eight individuals from Exp#1 were also part of Exp#2; however, other aliquots were used. Furthermore, 26 additional serum HC samples remaining from Exp#1 were included in the 40-plex mesoscale analysis in Exp#2 (Supporting Information Table S3).

Biomarkers Measurements

sCD163 was measured in serum and CSF using an in-house ELISA.^{3,24} ELISAs was used to measure CSF levels of total human Tau (h-Tau), phosphorylated threonine 181-Tau (p-Tau), Abeta₁₋₄₂ (all by Innostest), and total α -syn (Analytica Jena Roboscreen GmbH, Leipzig, Germany). MSD MULTI-SPOT Assay System (Meso Scale Discovery, MD) was used to measure 40 different molecules in serum and CSF (see Supporting Information).

α -Syn and sCD163 Association

Evaluation of sCD163- α -syn binding was done using Microscale Thermophoresis.

Monocyte-derived macrophages (MDMs) from isolated and matured human monocytes²⁵ were stimulated with 100 nM, 1 μ M, or 5 μ M monomeric or fibrillar α -syn for 6 or 24 hours, followed by sCD163-ELISA measurement in supernatants.

Differentiated THP-1 macrophage-like cells or BV-2 murine microglia cells were used to study ¹²⁵I- α -syn fibril uptake (50 ng/mL) alone or with sCD163 (5 μ g/mL) as a co-treatment or pre-treatment. Full-length (domains 1-9) or truncated (domains 1-5) sCD163 was used, and when stated, lipopolysaccharide (LPS) was removed from sCD163 preparations as described previously²⁶ (see Supporting Information).

Statistical Analyses

GraphPad Prism V7, JMP 14, and STATA v15 IC were used for statistical analyses where normality was first informed (see Supporting Information).

Results

sCD163 as a Biomarker Related to Cognition (Exp#1)

First, we investigated any PD-related changes in sCD163 in Exp#1: biobank samples from 109 patients with PD and 44 HCs (Supporting Information Fig. S1; Supporting Information Table S1). CSF-sCD163 was elevated in late PD (Fig. 1A) with no sex differences. Serum-sCD163 levels were influenced by sex and treatment (two-way ANOVA [$F(7, 140) = 2.86, P = 0.008$], sex effect $P = 0.039$, treatment effect $P = 0.017$). Therefore, we separated the data by sex, and to eliminate the treatment variable, we analyzed only treated patients. We found elevated serum-sCD163 levels in women with late PD (versus early), but not in men (Fig. 1B). To confirm that changes in CSF-sCD163 were not a simple leakage from serum, we calculated the amount of intrathecally produced and serum-derived sCD163 using the ratio of albumin CSF/serum as reference (when available).²⁷ We found no difference in the amount of CSF-sCD163 of serum origin (late PD: 0.0132 ± 0.001 , early PD: 0.0139 ± 0.001). In contrast, intrathecally produced sCD163 was higher in late PD (0.0739 ± 0.037) than in early PD (0.0601 ± 0.019 , $P = 0.03$), confirming elevated cerebral CD163 shedding.

Interestingly, for patients with PD, CSF-sCD163 correlated positively with well-characterized neurodegenerative CSF markers (α -syn, h-Tau, and p-Tau), even after compensating for age and disease duration (Fig. 1C–E; Supporting Information Table S4). sCD163 also correlated with h-Tau (Spearman $r = 0.477$, $P < 0.01$) and p-Tau ($r = 0.36$, $P < 0.05$) in HCs. Because these biomarkers have been related to PD symptomatology, we examined putative correlations between sCD163 and patients' clinical scores. Remarkably, CSF-sCD163 was negatively correlated with the cognitive scores Montreal Cognitive Assessment (MoCA) and Mini-Mental State Examination (MMSE) in the patients with PD (Fig. 1F–H). Serum-sCD163 also correlated positively with neuronal CSF markers (Fig. 1I–K), even after compensation for covariance (Supporting Information Table S4). However, serum-sCD163 did not correlate with cognitive scores. Neither serum- nor CSF-sCD163 correlated with other clinical parameters [Unified Parkinson's Disease Rating Scale part III (UPDRS-III) or Levodopa Equivalent Daily Dose (LEDD)] after compensating for covariables (data not shown).

Confirmation of sCD163 as a Biomarker in PD (Exp#2)

We aimed to confirm these findings in a second independent measurement with samples from additional

individuals in the same biobank (Exp#2) with a 2-year time gap between experiments (Supporting Information Fig. S1; Supporting Information Table S2). Indeed, we corroborated an increase in CSF-sCD163 in late PD in Exp#2 (Fig. 2A). Again, the estimated amount of sCD163 in CSF with serum origin was similar across groups (late PD: 0.011 ± 0.002 , early PD: 0.014 ± 0.002 , HCs: 0.009 ± 0.002), whereas the intrathecally produced sCD163 increased in late PD (0.109 ± 0.047) versus early PD (0.071 ± 0.018 , $P = 0.004$) and versus HCs (0.074 ± 0.023 , $P = 0.02$). This suggests increased cerebral sCD163 production. We also confirmed the sex difference observed for serum-sCD163 with an increase in female patients only (Fig. 2B).

In agreement with observations from Exp#1, CSF-sCD163 correlated with the neuronal CSF markers (α -syn, h-Tau, and p-Tau) in Exp#2 (Fig. 2C–E). CSF-sCD163 in HCs also correlated with h-Tau (Spearman $r = 0.61$, $P < 0.05$) and p-Tau ($r = 0.62$, $P < 0.01$). Moreover, in Exp#2, CSF-sCD163 was significantly correlated with levels of A β_{1-42} (Fig. 2F). The association between serum-sCD163 and CSF biomarkers showed a similar pattern, with significant correlation with α -syn and p-Tau (Fig. 2J–M).

Notably, this was also true for cognitive scores, which decreased while sCD163 increased in patients with PD (Fig. 2G–I). Age influenced cognition scores and sCD163; however, CSF-sCD163 levels remained significantly associated with cognitive decline after adjusting for age at visit alone or in combination with age at onset or disease duration for the MMSE O + C scores (Supporting Information Table S5). Therefore, a 0.1-mg/L increase in CSF-sCD163 corresponded to a decline of ~ 3 MMSE O + C score. When adjusting for both age at visit and disease duration, the expected MMSE decline would be ~ 1.8 (Supporting Information Table S5). This suggests that sCD163 is associated with cognitive decline, even when patient age and disease duration are considered.

Other CSF and Serum Biomarkers (Exp#2)

To define the patients' immune profile, we measured 40 immune-related serum and CSF biomarkers from Exp#2. In CSF, we observed that of 16 reliable assays (Supporting Information Table S3; Supporting Information Fig. S2), 7 showed PD-related changes with $P < 0.05$: VCAM-1 (vascular cell adhesion molecule 1), ICAM-1 (Intercellular Adhesion Molecule 1), IL-8, SAA (Serum amyloid A), PIGF (Placental growth factor), IL-15, and VEGF-D (Vascular endothelial growth factor-D) were increased in patients with PD (Fig. 3A–K). However, none remained significant after Bonferroni correction ($\alpha = 0.0031$).




FIG. 1. Identification of soluble CD163 (sCD163) as a biomarker in Parkinson's disease (PD) (Exp#1). sCD163 levels in cerebrospinal fluid (CSF) (A) and serum (B) from healthy control subjects (HCs) or patients with PD at early (<5 years) or late (≥5 years since diagnosis) stage. Serum measurements were separated into female (F) and male (M) groups as a result of a priori identification of sex difference and include only treated patients. Data are mean ± SD, and values were log transformed to achieve normality. CSF-sCD163 for all patients with PD was correlated with well-characterized neurodegenerative CSF markers: (C) alpha-synuclein (α-syn), (D) total Tau (h-Tau), and (E) phosphorylated Tau (p-Tau), as well as with clinical cognitive scores: (F) the Montreal Cognitive Assessment (MoCA), (G) the Mini-Mental State Examination (MMSE) original score (O), or (H) original plus converted from MoCA (O + C). (I) CSF levels of α-syn (J) h-Tau (only trend), and (K) p-Tau correlated with serum-sCD163. P values for one-way ANOVA with Tukey's multiple comparisons test values, respectively, Spearman two-tailed P values (* $P < 0.05$, ** $P < 0.01$, *** $P < 0.001$, **** $P < 0.0001$), Spearman r , and best-fit slope with 95% confidence intervals are plotted.




FIG. 2. Confirmation of soluble CD163 (sCD163) as a biomarker in Parkinson's disease (PD) (Exp#2). sCD163 measurements in (A) cerebrospinal fluid (CSF) and (B) serum from healthy control subjects (HCs) or patients with PD with early (<5 years) or late (≥ 5 years since diagnosis) status, with serum measurements being separated into female (F) and male (M) groups as a result of a priori identification of sex difference and include only treated patients. Data are mean $\pm$ SD, and values were log transformed to achieve normality. CSF-sCD163 for all patients with PD correlated with well-characterized neurodegenerative/PD-CSF markers, (C) alpha-synuclein (α -syn), (D) total Tau (h-Tau), (E) phosphorylated Tau (p-Tau), and (F) Abeta₁₋₄₂ (Abeta42), as well as with clinical cognitive scores, (G) the Montreal Cognitive Assessment (MoCA), (H) the Mini-Mental State Examination (MMSE) original score (O), or (I) original plus converted from MoCA (O + C). (J) CSF α -syn, (K) h-Tau (trend only), and (L) p-Tau correlated with serum-sCD163. No correlation was found for serum-sCD163 and (M) Abeta42 in CSF; P values for ordinary or Kruskal-Wallis (nonparametric) one-way ANOVA with Tukey's or Dunn's multiple comparisons test values, respectively, Spearman two-tailed P values (* P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001), Spearman r , and best-fit slope with 95% confidence intervals are plotted. Further information on cognitive scoring correlations with respect to progression status and covariance can be found in Supporting Information Table S5.

In serum, only 4 markers (of 27 reliably assayed markers; Supporting Information Table S3; Supporting Information Fig. S2) showed PD-related changes with $P < 0.05$ (Fig. 3L–S): VCAM-1 was increased in patients' serum, and IL-15 and VEGF-D were both increased in late versus early PD (Fig. 3L,R–S), whereas VEGF-C was decreased in all patients (Fig. 3M). Nevertheless, none remained statistically significant after Bonferroni correction ($\alpha = 0.0018$).

Correlation Between CSF and Serum Biomarkers With sCD163 (Exp#2)

To better describe the immune profile related to increased sCD163, we investigated any association with sCD163 and other immune molecules in CSF and serum (Fig. 4A–D). CSF-sCD163 was positively correlated with several biomarkers in CSF, both when examining all patients with PD and with early/late separation, even after Bonferroni correction. The strongest significant correlations for CSF-sCD163 observed at all disease stages were those with IL-15 ($r = 0.72$) (Fig. 4G), ICAM-1 ($r = 0.63$), VCAM-1 ($r = 0.61$), and Flt-1 (VEGFR1, $r = 0.51$). Several chemokines were also strongly correlated with CSF-sCD163 in late PD: CXCL10 ($r = 0.52$), CCL4 ($r = 0.51$), and CCL2 ($r = 0.44$) (Fig. 4A,B).

In serum, the sCD163 correlations were weaker and fewer (Fig. 4C,D): serum-sCD163 was correlated with CRP ($r = 0.41$), IL-6 ($r = 0.39$), ICAM-1 ($r = 0.34$), and SAA ($r = 0.35$) in all patients and with TNF- α ($r = 0.55$), IL-12/IL-23p ($r = 0.47$), and VCAM-1 ($r = 0.57$), correlating at late PD. The strong sCD163/IL-15 correlation observed in CSF was absent in serum as a result of sex discrepancies in CD163 and not in IL-15.

Phenotypic Related Biomarkers (Exp#2)

In CSF, besides sCD163, only IL-15 had a strong negative correlation with MMSE (O + C) and a significant linear regression (Fig. 4E,F,H) as expected, because sCD163 and IL-15 in CSF were strongly correlated (Fig. 4G). Interestingly, IL-15 was the only serum biomarker found to negatively correlate and have a significant linear regression with MMSE (O + C) (Fig. 4I). Other CSF markers also showed a significant negative (but weaker) correlation with cognitive scores MMSE (O + C), although only in late PD: IL-7 ($r = -0.48$), C-C Motif Chemokine Ligand 2 (CCL2) ($r = -0.33$), IL-8 ($r = -0.32$), and PIGF ($r = -0.31$) (Fig. 4E,F). Only serum-VEGF-A showed a significant negative correlation and linear regression with UPDRS III scores (Fig. 4J). Accordingly, serum-VEGF-A displayed UPDRS III prognostic potential in our mathematical analysis (see later; Supporting Information Fig. S5A). No CSF biomarker correlated with UPDRS III (data not shown).

Mathematical Modeling of sCD163 as Phenotypic Biomarker in PD (Exp#2)

To statistically evaluate the potential of sCD163 and the other assayed markers to predict PD diagnosis (PD versus HC) and PD phenotypic scores (UPDRS-III, MoCA, MMSE O, and MMSE O + C), we used receiver-operating characteristic (ROC) analysis [area under the curve (AUC) estimates] and linear regression (regression slopes) (Supporting Information Figs. S3, S5, and S6). In CSF, sCD163, VCAM-1, ICAM-1, IL-15, IL-8, SAA, PIGF, and VEGF-C and in serum, sCD163 (female), CRP (female), and VCAM-1 (all) showed statistical power to predict PD (Fig. 4K–L; Supporting Information S3). Principal component analysis of CSF data confirmed sCD163, VCAM-1, ICAM-1, IL-15, and IL-8 as markers associated with PD diagnosis (Supporting Information Fig. S4). In CSF, the best individual markers to predict scores of all three cognitive scales used were sCD163, SAA, and IL-15, while in serum, they were SAA, CRP, and IL-8 (Supporting Information Figs. S5 and S6).

Therefore, our analysis showed the prognostic power of serum- and CSF-sCD163 for PD diagnosis and cognitive scores (in CSF only). However, the specificity and sensitivity of sCD163 were not enough to be used alone. Therefore, we aimed to compute combined biomarker panels to address PD diagnosis and phenotypic scores using three variants of stepwise forward modeling with variable probability for biomarkers to enter the model (M) and with sCD163 being forced in M3 (Supporting Information Tables S6 and S7). The best prediction model of serum and CSF biomarker panels was selected and plotted as PD prediction ROC plots (Fig. 4M,N) or as goodness-of-fit plots for PD phenotypic scores (Supporting Information Fig. S7). M3 including sCD163 together with other independently contributing biomarkers resulted in the best prediction of PD diagnosis, both in serum and CSF (both AUC 0.88). Likewise, M3 including sCD163 [in serum together with IL-15, CRP, CCL2 (monocyte chemoattractant protein-1 (MCP-1)), PIGF, and IL-7; and in CSF together with p-Tau, IL-7, and IL-8] resulted in the best prediction of MoCA scores with the highest R^2 values (serum 0.29, CSF 0.32) (Supporting Information Fig. S7B,F). Therefore, sCD163 in serum and CSF holds promising potential as a significant contributor in a biomarker panel to address PD diagnosis and cognitive scores and deserves future investigation.

Exploring *in vitro* Interaction Between CD163 and α -Syn

Because sCD163 positively correlated with α -syn in CSF, we sought to further investigate any possible relation between them *in vitro*. No signs of direct cointeraction were observed using Microscale




FIG. 3. Screening of other cerebrospinal fluid (CSF) and serum biomarkers (Exp#2). Sixteen different CSF biomarkers and 27 serum biomarkers from the 40-plex mesoscale assay had values greater than LLOD (lower limit of detection) and were tested for differences (**A-F** and **L-P**) between healthy

Thermophoresis in any condition assayed (Supporting Information Fig. S7). However, incubation of human primary MDMs with increasing concentrations of monomeric and fibrillar α -syn induced macrophage activation and dose-dependent sCD163 shedding (Fig. 5A), supporting the inflammatory capacity of α -syn and its ability to induce CD163 cleavage, as seen for LPS (positive control).

We then evaluated the effect of sCD163 on α -syn uptake using human monocytic THP-1 cells differentiated into macrophages and mouse microglia BV-2 cells to obtain information from the two myeloid cells involved in PD. Cells were incubated with radiolabeled α -syn fibrils alone or with recombinant sCD163 as cotreatment or pretreatment (30 minutes) (Fig. 5B). After 5 minutes, THP-1 cells increased α -syn internalization when co-treated or pre-treated with sCD163 compared with α -syn alone. In BV-2 cells, the uptake of α -syn increased after 5 and 15 minutes of pre-treatment with sCD163, whereas co-incubation increased α -syn uptake only after 45 minutes (Fig. 5C). This increased α -syn fibril uptake in THP-1-derived macrophages was specifically associated with full-length sCD163 because LPS removal did not affect uptake, whereas truncation of the sCD163 protein did (Fig. 5D).

Discussion

Genetic data suggest that the PD inflammatory component is driven by the myeloid immune compartment, which includes microglia and monocytes/macrophage.²⁸ Numerous studies show alterations on immune biomarkers in CSF and serum associated with symptoms in patients with PD.¹¹ However, these biomarkers are not cell type specific and therefore provide no information on cellular relevance in the disease mechanism. Here, we show that CSF-sCD163, a monocyte/macrophage-specific biomarker,¹⁴ increases in late versus early PD, hence suggesting increasing monocytic activation with disease duration. sCD163 was associated with well-accepted PD biomarkers and inversely correlated with cognitive scores, supporting a role for monocytes in neurodegeneration. Serum-sCD163 was also increased, although only in female patients, suggesting a sex-distinctive monocytic response. This increase in sCD163 levels is indicative of monocytic activation occurring in parallel with variations in cytokines,

chemokines, and angiogenic factors. These changes were different in CSF versus serum, supporting a distinctive immune profile in the brain and periphery. Step-forward regression models and ROC analysis confirmed sCD163 as a predictor of PD and cognitive scores. In addition, mathematical models confirmed the prognostic potential of sCD163 in combination with other biomarkers in serum and CSF. Interestingly, our *in vitro* studies suggest that α -syn itself can induce macrophage activation and sCD163 shedding, while sCD163 might enhance α -syn uptake by myeloid cells and participate in the clearance of α -syn. In conclusion, our data suggest that sCD163 is a promising biomarker associated with inflammation in PD, thereby supporting a role for α -syn in monocyte activation and sCD163 shedding that could have direct consequences for α -syn processing.

Our analysis of the two experiments in the PD cohort showed increased sCD163 in biofluids from patients with PD. CD163 is cleaved by ADAM17,²² which also cleaves VCAM-1 and ICAM-1.^{29,30} ADAM17 activity is enhanced by inflammatory signals, such as Toll-like receptor 2/4 (TLR2/4) activation; therefore, sCD163 levels are related to monocyte activation and associated with severity of diseases with an inflammatory component.¹⁴ Indeed, sCD163 is widely used as an inflammatory marker for disease prognosis in multiple disorders, including diabetes, asthma, and atherosclerosis.³¹ Two diseases genetically related to PD also show increased sCD163: Crohn's syndrome³² and Gaucher's disease,³³ confirming a shared common myeloid disease mechanism. The inflammatory signals responsible for CD163 shedding in PD are yet unknown, but α -syn may be a contributor because it can activate TLR2/4,² which are upregulated in the monocytes of patients with PD.^{4,34} Accordingly, we demonstrated sCD163 shedding in human primary MDMs incubated with fibrillar α -syn, confirming the inflammatory ability of α -syn in macrophages³⁵ and its relation to the increase of sCD163 in PD.

Our data from this cross-sectional cohort showed increased sCD163 with time from onset, supporting increasing involvement of CD163⁺ monocytes in the different PD stages. Higher CSF-sCD163 levels were not a simple leakage from serum, because the increase was not found in male serum. Furthermore, the estimated amount of sCD163 produced intrathecally was, indeed, elevated in PD. The sCD163 found in CSF can

controls (HCs) and patients with Parkinson's disease (PD) groups, or (G,H and R,S) between PD stages: early (<5 years) and late ($\geq$ 5 years since diagnosis), or (I-K) concerning treatment (T) status with or without (UT) levodopa. (I,Q) MCP-1 (CCL2) (I) and IL-6 (Q) were sex separated as a result of a priori identification of sex differences. Twenty-six additional HCs' serum samples from Exp#1 were added for biomarkers unaffected by extra freezing/thaw cycle (M,O,P,R). Data are mean $\pm$ SD. *P* values are shown for unpaired *t*-test or Mann-Whitney *U* test, or for ordinary or (nonparametric) Kruskal-Wallis one-way ANOVA with Tukey's or Dunn's multiple comparisons test values, respectively, as appropriate: **P* < 0.05, ***P* < 0.01, ****P* < 0.001, *****P* < 0.0001. (*) indicates one outlier from early PD was removed based on ROUT *Q* = 0.1%; if including the outlier: *P* = 0.052. Biomarkers with no differences (or no statistical trend) between groups are shown in Supporting Information Fig. S2. LLOQ, lower limit of quantification; ULOQ, upper limit of quantification.




FIG. 4. Correlations of soluble CD163 (sCD163) with other analytes, biomarker correlations with phenotypic scores, and receiver-operating characteristic (ROC) analysis of sCD163 and associated panels for Parkinson's disease (PD) diagnosis (Exp#2). (A–D) Cerebrospinal fluid (CSF)- (A,B) and serum-sCD163 (C,D) were compared with all 40-plex biomarkers with values greater than the lower limit of detection (LLOD) measured in CSF ($n = 16$) and serum ($n = 27$), respectively. (A,C) Spearman correlation P value (the green color shows those with a P value less than the Bonferroni-adjusted threshold [$P < 0.0031$ for CSF and $P < 0.0018$ for serum]) and (B,D) Spearman r values are plotted as heat maps. Correlations are done for all patients with PD or separated as late (≥ 5 years since diagnosis) or early (< 5 years since diagnosis) PD status. (E,F) CSF biomarkers with values greater than LLOD are correlated with Mini-Mental State Examination (MMSE) [original scores + converted from Montreal Cognitive Assessment (MoCA) (O + C)] and plotted as heat maps for (E) Spearman P and (F) r values. Correlations are done for all patients with PD or separated as late (≥ 5 years) or early (< 5 years since diagnosis) PD status. (G) CSF interleukin (IL)-15 had the strongest correlation with MMSE O + C; plotted with the Spearman P and r [95% confidence interval (CI)] and the equation for the linear regression with a slope significantly different from 0. (H) IL-15 was the only biomarker in serum with a significant correlation and linear regression with MMSE O + C. (I) IL-15 in CSF had a strong correlation and linear regression with CSF-sCD163. (J) Serum VEGF-A was the only biomarker with a significant correlation and linear regression with the Unified Parkinson's Disease Rating Scale part three (UPDRS III) score. Spearman two-tailed P values ($*P < 0.05$, $**P < 0.01$, $***P < 0.001$, $****P < 0.0001$). (K–N) ROC curves for prediction of PD related to sCD163: (K) CSF-sCD163 alone, (L) serum-sCD163 alone when separated by sex, (M) CSF M3 biomarker panel, including sCD163, h-Tau, Abeta_{1–42} (Abeta42), SAA, and VEGF-A x10, and (N) serum M3 biomarker panel, including sCD163, VEGF-D/100, VCAM-1/10,000, Fit1/100, IL-15, IL-10, and Macrophage Inflammatory Proteins (MIP)1 β /100. ROC curves for other biomarkers with $P < 0.05$ are shown in Supporting Information Fig. S3. AUC, area under the ROC curve.

be produced by CD163-expressing meningeal, choroid plexus, and perivascular macrophages, as well as by infiltrating macrophages.¹⁷⁻¹⁹ CD163 is a myeloid marker whose expression is lost during microglia development and is therefore absent in adult microglia, as recently shown in single-cell RNA studies.¹⁵⁻¹⁷ In studies conducted by others and ourselves, an increase in CD163⁺ cells has been observed in brain parenchyma in rodent PD models^{9,10} and post mortem brains of patients with Alzheimer's disease and PD.³⁶ Thus, sCD163 could be partially produced by infiltrating CD163⁺ monocytes/macrophages and their subsequent local activation. Accordingly, CSF-sCD163 was correlated with CCL2, CCL4, and CXCL10, chemokines involved in monocyte recruitment and previously correlated with PD symptoms.³⁷⁻⁴⁰ More importantly, sCD163 was also strongly correlated with regulators of angiogenesis, blood-brain barrier (BBB) extravasation, and/or monocyte brain infiltration or recruitment,⁴¹⁻⁴⁵ which have been reported to be increased in PD,⁴⁶⁻⁴⁸ namely, ICAM-1, VCAM-1, and VEGF-D in both serum and CSF, and IL-8, IL-15, and PlGF only in CSF.

sCD163 is a biomarker widely used to measure an inflammatory component. Accordingly, in PD serum, sCD163 was associated with an increase in the acute-phase proteins SAA and CRP, which were previously associated with motor impairment and PD dementia.^{37,49-51} Moreover, serum-sCD163 also correlated with the proinflammatory cytokines TNF- α and IL-6, as well as IL-12/IL-23p40 and IL-15, both elevated in PD serum. IL-12/IL-23p40 is produced by dendritic cells (also CD163⁺) on TLR activation, whereas IL-15 induces dendritic cell differentiation; thus, both are involved in T cell modulation.^{52,53} IL-12/IL-23p40 was previously found to be increased and important in PD and Crohn's disease.^{54,55} Taken together, patients' CSF-sCD163 correlated with immune molecules associated with angiogenesis, cell infiltration, and T cell activation, relating monocyte activation to leukocytes recruitment to sites of inflammation in the brain, whereas serum-sCD163 correlations indicated monocyte activation in relation to proinflammatory events. Overall, the immune profile in PD suggested the occurrence of an inflammatory event leading toward a permissive environment for recruitment of adaptive and innate immune cells to the brain.

Surprisingly, IL-15 was the only biomarker elevated in PD serum and CSF correlating with cognitive scores in both biofluids, thus revealing that IL-15 may be another putative biomarker. However, despite the relevance of IL-15 in BBB permeability, brain immunomodulation, and its connection to mood and memory,⁵⁶ our ROC analysis for the ability of IL-15 to predict PD diagnosis had a lower AUC with higher variation than sCD163. Moreover, in contrast with CD163, IL-15 is produced by a variety of cells,

including neurons, and is therefore not monocyte-lineage specific like sCD163.⁵⁶ Therefore, our data suggest a relevance of IL-15 in PD, but they do not provide information on specific cell types involvement in PD and cognition, and do not reflect the sex difference in the disease, which might be both a disadvantage and a gain.

Serum-sCD163 levels were only significantly changed in women with PD. To our knowledge, only urate has been proposed as a PD biomarker with sex relevance.⁵⁷ Sex differences in the immune system are long acknowledged.⁵⁸ PD has a sex bias, and immune-related sex differences have been shown in PD.⁵⁴ Sex-specific changes in serum-sCD163 could be related to female-male differences in PD incidence⁵⁹ and symptomatic presentation.⁶⁰ Accordingly, we previously showed sex-dependent variation in the response of PD blood monocytes *in vitro*.³ Therefore, the observed differences could be a result of sex-specific immune divergences with consequences for the risk and presentation of PD.

CSF-sCD163 was strongly correlated with the disease biomarkers α -syn, h-Tau, and p-Tau, which have been associated with PD diagnosis, clinical symptoms, and cognition.^{61,62} Although non-significant, we unexpectedly observed elevated α -syn level in PD compared with HCs in both experiments. α -Syn levels are usually lower in PD versus HCs, and so it was when the average of all informed samples in the biobank were compared (data not shown). Our observation most likely reflects random sampling from the biobank, the slightly lower age of the HCs, and the low number of HCs samples with α -syn measurements used here. Nonetheless, α -syn has been reported to longitudinally increase with time in PD,⁶³ and our data here suggest a parallel increase of sCD163. The observed α -syn/CD163 correlation in PD could be directly related to the ability of α -syn to induce monocytic activation and sCD163 production. Similarly, h-Tau and p-Tau also increase, probably reflecting progressive neurodegeneration.⁶³ We found that higher sCD163 levels were associated with lower cognitive scores, supporting a driving role for monocytes in the cognitive component of PD. This agrees with imaging studies showing that cognitive scores in PD dementia correlated with increased immune activation and reduced cortical glucose metabolism.⁶⁴ Furthermore, changes in monocytes seem more relevant in those patients with PD with higher risk for development of cognitive problems.⁴ Altogether, our data support a relation between monocyte activation and the PD cognitive component.

sCD163 function is unclear, but it was shown to potentiate IL-10 expression in allergen-activated PBMCs⁶⁵ and to inhibit T cell activation/proliferation,⁶⁶ hence promoting inflammatory resolution. CD163 facilitates the hemoglobin-haptoglobin



uptake extracellular α -syn. *In vitro*, T cell-internalized sCD163 binds myosin,⁶⁹ a molecule involved in phagocytosis.⁷⁰ Therefore, sCD163 might induce intracellular pathways that would influence α -syn phagocytosis and thus resolve inflammation. Indeed, sCD163 required time to exert its effect on BV-2 cells, supporting induction of certain intracellular cascades. Otherwise, this delay could be caused by species differences. Notably, to obtain robust changes in our *in vitro* experiments, a high-end (5 mg/L) sCD163 concentration was used compared with reported physiologically relevant serum level (1–6 mg/L, with 4.2 mg/L being the highest in our cohort). Further investigation is required to fully understand the sCD163 effect on myeloid response to α -syn during PD.

The findings of this study may be somewhat limited by the cross-sectional study design, low numbers of HCs, and potential confounding inflammatory diseases (with anti-inflammatory medication) among study participants. The increase in sCD163 in late PD compared with early PD and HCs, as well as the negative correlation with cognitive scores, suggests a relation between sCD163 and PD stages. However, we cannot exclude a possible relation with sCD163 and cognitive decline during aging in other synucleinopathies and neurodegenerative diseases. Nevertheless, our mathematical modeling proposes a prognostic power for biomarker panels including sCD163 as one of the analytes. However, this has to be examined in a prospective longitudinal study to truly determine the potential of sCD163 as a PD and cognition biomarker.

In conclusion, we show a PD-related increase in sCD163 in serum (in women) and CSF, supporting a role for monocytes in the PD immune response. The increase in sCD163 paralleled those of accepted neuronal biomarkers, therefore relating monocytic and neuronal events. In addition, higher sCD163 levels were associated with lower cognitive scores, indicative of an association between the monocytes' immune response and cognitive decline. The CSF-sCD163 increase was associated with immune biomarkers, suggestive of a permissive BBB and activation of adaptive immune cells. Moreover, our *in vitro* studies suggest that α -syn could activate myeloid cells and induce sCD163 release, which enhances the myeloid cells' capacity to uptake α -syn, indicative of a relevant role for disease progression. ■

Acknowledgments: We acknowledge the invaluable technical help provided by Gitte Ulbjerg Toft and Gitte Fynbo Biller (Department of Biomedicine, Aarhus University) and by Helle Hauser Ryom and Christina Strande Søndergaard (Department of Clinical Biochemistry, Aarhus University Hospital). We are grateful to Prof. Dr. Mart Saarma (Helsinki University) for scientific support and Prof. Poul Henning Jensen (Aarhus University) for kindly providing the human α -syn protein. Samples were obtained from the Neuro-Biobank of the University of Tuebingen, Germany (<https://www.hih-tuebingen.de/en/about-us/core-facilities/biobank/>), which is supported by the local University, the Hertie Institute, and the DZNE. Funding support for the research covered by this article was

provided by the Michael J. Fox Foundation (M.R.-R.), the Bjarne Saxhof Fund administered through the Danish Parkinson's Foundation (M.R.-R.), the Aarhus University Research Foundation, AU IDEAS center NEURODIN (M.R.-R.), and the Novo Nordisk Foundation (DEO, NNF17OC0028806). S.A.F. is funded by a PhD fellowship from the PhD School at the Health Faculty, Aarhus University.

References

1. Tansey MG, Romero-Ramos M. Immune system responses in Parkinson's disease: early and dynamic. *Eur J Neurosci* 2019;49(3):364–383.
2. Ferreira SA, Romero-Ramos M. Microglia response during Parkinson's disease: alpha-synuclein intervention. *Front Cell Neurosci* 2018;12:247.
3. Nissen SKShrivastava K, Schulte C, et al. Alterations in blood monocyte functions in Parkinson's disease. *Mov Disord* 2019;1711–1721.
4. Wijeyekoon RSKronenberg-Versteeg D, Scott KM, et al. Peripheral innate immune and bacterial signals relate to clinical heterogeneity in Parkinson's disease. *Brain Behav Immun* 2020;87:473–488.
5. Schlachetzki JCM, Prots I, Tao J, et al. A monocyte gene expression signature in the early clinical course of Parkinson's disease. *Sci Rep* 2018;8(1):10757.
6. Kustrimovic N, Comi C, Magistrelli L, et al. Parkinson's disease patients have a complex phenotypic and functional Th1 bias: cross-sectional studies of CD4+ Th1/Th2/T17 and Treg in drug-naïve and drug-treated patients. *J Neuroinflammation* 2018;15(1):205.
7. Storelli E, Cassina N, Rasini E, Marino F, Cosentino M. Do Th17 lymphocytes and IL-17 contribute to Parkinson's disease? A systematic review of available evidence. *Front Neurol* 2019;10:13.
8. Brochard V, Combadiere B, Prigent A, et al. Infiltration of CD4+ lymphocytes into the brain contributes to neurodegeneration in a mouse model of Parkinson disease. *J Clin Invest* 2009;119(1):182–192.
9. Tentillier N, Etzerodt A, Olesen MN, et al. Anti-inflammatory modulation of Microglia via CD163-targeted glucocorticoids protects dopaminergic neurons in the 6-OHDA Parkinson's disease model. *J Neurosci* 2016;36(36):9375–9390.
10. Harms AS, Delic V, Thome AD, et al. Alpha-synuclein fibrils recruit peripheral immune cells in the rat brain prior to neurodegeneration. *Acta Neuropathol Commun* 2017;5(1):85.
11. King E, Thomas A. Systemic inflammation in Lewy body diseases: a systematic review. *Alzheimer Dis Assoc Disord* 2017;31(4):346–356.
12. Xu S, Lu J, Shao A, Zhang JH, Zhang J. Glial cells: role of the immune response in ischemic stroke. *Front Immunol* 2020;11:294.
13. Polfliet MM, Fabrick BO, Daniels WP, Dijkstra CD, van den Berg TK. The rat macrophage scavenger receptor CD163: expression, regulation and role in inflammatory mediator production. *Immunobiology* 2006;211(6–8):419–425.
14. Etzerodt A, Moestrup SK. CD163 and inflammation: biological, diagnostic, and therapeutic aspects. *Antioxid Redox Signal* 2013;18(17):2352–2363.
15. Keren-Shaul H, Spinrad A, Weiner A, et al. A unique microglia type associated with restricting development of Alzheimer's disease. *Cell* 2017;169(7):1276–1290.e1217.
16. Bian ZGong Y, Huang T, et al. Deciphering human macrophage development at single-cell resolution. *Nature* 2020;582:571–576.
17. Jordao MJC, Sankowski R, Brendecke SM, et al. Single-cell profiling identifies myeloid cell subsets with distinct fates during neuroinflammation. *Science* 2019;363(6425):eaat7554.
18. Kim WK, Alvarez X, Fisher J, et al. CD163 identifies perivascular macrophages in normal and viral encephalitic brains and potential precursors to perivascular macrophages in blood. *Am J Pathol* 2006;168(3):822–834.
19. Rezaie P, Microglia in Fetal MD. Adult human brain can be distinguished from other mononuclear phagocytes through their lack of CD163 expression. *Neuroembryol Aging* 2003;2(3):130–133.

20. Moller HJ, Peterslund NA, Graversen JH, Moestrup SK. Identification of the hemoglobin scavenger receptor/CD163 as a natural soluble protein in plasma. *Blood* 2002;99(1):378–380.
21. Nielsen MC, Andersen MN, Rittig N, et al. The macrophage-related biomarkers sCD163 and sCD206 are released by different shedding mechanisms. *J Leukoc Biol* 2019;106(5):1129–1138.
22. Etzerodt A, Maniecki MB, Moller K, Moller HJ, Moestrup SK. Tumor necrosis factor alpha-converting enzyme (TACE/ADAM17) mediates ectodomain shedding of the scavenger receptor CD163. *J Leukoc Biol* 2010;88(6):1201–1205.
23. Litvan I, Bhatia KP, Burn DJ, et al. Movement disorders society scientific issues committee report: SIC task force appraisal of clinical diagnostic criteria for Parkinsonian disorders. *Mov Disord* 2003;18(5):467–486.
24. Moller HJ, Hald K, Moestrup SK. Characterization of an enzyme-linked immunosorbent assay for soluble CD163. *Scand J Clin Lab Invest* 2002;62(4):293–299.
25. Nielsen MC, Andersen MN, Moller HJ. Monocyte isolation techniques significantly impact the phenotype of both isolated monocytes and derived macrophages in vitro. *Immunology* 2020;159(1):63–74.
26. Teodorowicz M, Perdijk O, Verhoek I, et al. Optimized triton X-114 assisted lipopolysaccharide (LPS) removal method reveals the immunomodulatory effect of food proteins. *PLoS One* 2017;12(3):e0173778.
27. Galea J, Cruickshank G, Teeling JL, et al. The intrathecal CD163-haptoglobin-hemoglobin scavenging system in subarachnoid hemorrhage. *J Neurochem* 2012;121(5):785–792.
28. Raj T, Rothamel K, Mostafavi S, et al. Polarization of the effects of autoimmune and neurodegenerative risk alleles in leukocytes. *Science* 2014;344(6183):519–523.
29. Scheller J, Chalaris A, Garbers C, Rose-John S. ADAM17: a molecular switch to control inflammation and tissue regeneration. *Trends Immunol* 2011;32(8):380–387.
30. Tsakadze NL, Sithu SD, Sen U, English WR, Murphy G, D'Souza SE. Tumor necrosis factor-alpha-converting enzyme (TACE/ADAM-17) mediates the ectodomain cleavage of intercellular adhesion molecule-1 (ICAM-1). *J Biol Chem* 2006;281(6):3157–3164.
31. Moller HJ. Soluble CD163. *Scand J Clin Lab Invest* 2012;72(1):1–13.
32. Dige A, Stoy S, Thomsen KL, et al. Soluble CD163, a specific macrophage activation marker, is decreased by anti-TNF-alpha antibody treatment in active inflammatory bowel disease. *Scand J Immunol* 2014;80(6):417–423.
33. Moller HJ, de Fost M, Aerts H, Hollak C, Moestrup SK. Plasma level of the macrophage-derived soluble CD163 is increased and positively correlates with severity in Gaucher's disease. *Eur J Haematol* 2004;72(2):135–139.
34. Grozdanov V, Bliederaeuser C, Ruf WP, et al. Inflammatory dysregulation of blood monocytes in Parkinson's disease patients. *Acta Neuropathol* 2014;128(5):651–663.
35. Klegeris A, Pelech S, Giasson BI, et al. Alpha-synuclein activates stress signaling protein kinases in THP-1 cells and microglia. *Neurobiol Aging* 2008;29(5):739–752.
36. Pey P, Pearce RK, Kalaitzakis ME, Griffin WS, Gentleman SM. Phenotypic profile of alternative activation marker CD163 is different in Alzheimer's and Parkinson's disease. *Acta Neuropathol Commun* 2014;2:21.
37. Santaella A, Kuiperij HB, van Rumund A, et al. Inflammation biomarker discovery in Parkinson's disease and atypical parkinsonisms. *BMC Neurol* 2020;20(1):26.
38. Brockmann K, Schulte C, Schneiderhan-Marra N, et al. Inflammatory profile discriminates clinical subtypes in LRRK2-associated Parkinson's disease. *Eur J Neurol* 2017;24(2):427–e426.
39. Chahine LM, Qiang J, Ashbridge E, et al. Clinical and biochemical differences in patients having Parkinson disease with vs without GBA mutations. *JAMA Neurol* 2013;70(7):852–858.
40. Rocha NP, Scalzo PL, Barbosa IG, et al. Cognitive status correlates with CXCL10/IP-10 levels in Parkinson's disease. *Parkinsons Dis* 2014;2014:903796.
41. Steiner O, Coisne C, Cecchelli R, et al. Differential roles for endothelial ICAM-1, ICAM-2, and VCAM-1 in shear-resistant T cell arrest, polarization, and directed crawling on blood-brain barrier endothelium. *J Immunol* 2010;185(8):4846–4855.
42. Janelidze S, Lindqvist D, Francardo V, et al. Increased CSF biomarkers of angiogenesis in Parkinson disease. *Neurology* 2015;85(21):1834–1842.
43. Stacker SA, Achen MG. Emerging roles for VEGF-D in human disease. *Biomolecules* 2018;8(1):1.
44. Hemstedt TJ, Bengtson CP, Ramirez O, Oliveira AMM, Bading H. Reciprocal interaction of dendrite geometry and nuclear calcium-VEGFD signaling gates memory consolidation and extinction. *J Neurosci* 2017;37(29):6946–6955.
45. Stone KP, Kastin AJ, Pan W. NFkB is an unexpected major mediator of interleukin-15 signaling in cerebral endothelia. *Cell Physiol Biochem* 2011;28(1):115–124.
46. Miklossy J, Doudet DD, Schwab C, Yu S, McGeer EG, McGeer PL. Role of ICAM-1 in persisting inflammation in Parkinson disease and MPTP monkeys. *Exp Neurol* 2006;197(2):275–283.
47. Sawada M, Imamura K, Nagatsu T. Role of cytokines in inflammatory process in Parkinson's disease. *J Neural Transm Suppl* 2006;70:373–381.
48. Perner C, Perner F, Gaur N, et al. Plasma VCAM1 levels correlate with disease severity in Parkinson's disease. *J Neuroinflammation* 2019;16(1):94.
49. Hall S, Janelidze S, Surova Y, Widner H, Zetterberg H, Hansson O. Cerebrospinal fluid concentrations of inflammatory markers in Parkinson's disease and atypical parkinsonian disorders. *Sci Rep* 2018;8(1):13276.
50. Sawada H, Oeda T, Umemura A, et al. Baseline C-reactive protein levels and life prognosis in Parkinson disease. *PLoS One* 2015;10(7):e0134118.
51. Mollenhauer B, Zimmermann J, Sixel-Doring F, et al. Baseline predictors for progression 4 years after Parkinson's disease diagnosis in the De Novo Parkinson cohort (DeNoPa). *Mov Disord* 2019;34(1):67–77.
52. Ma C, Panaccione R, Khanna R, Feagan BG, Jairath V. IL12/23 or selective IL23 inhibition for the management of moderate-to-severe Crohn's disease? *Best Pract Res Clin Gastroenterol* 2019;38–39:101604.
53. Patidar M, Yadav N, Dalai SK. Interleukin 15: a key cytokine for immunotherapy. *Cytokine Growth Factor Rev* 2016;31:49–59.
54. Brockmann K, Apel A, Schulte C, et al. Inflammatory profile in LRRK2-associated prodromal and clinical PD. *J Neuroinflammation* 2016;13(1):122.
55. Villumsen M, Aznar S, Pakkenberg B, Jess T, Brudek T. Inflammatory bowel disease increases the risk of Parkinson's disease: a Danish nationwide cohort study 1977–2014. *Gut* 2019;68(1):18–24.
56. Pan W, Wu X, He Y, et al. Brain interleukin-15 in neuroinflammation and behavior. *Neurosci Biobehav Rev* 2013;37(2):184–192.
57. Schwarzschild MA, Marek K, Eberly S, et al. Serum urate and probability of dopaminergic deficit in early "Parkinson's disease". *Mov Disord* 2011;26(10):1864–1868.
58. Klein SL, Flanagan KL. Sex differences in immune responses. *Nat Rev Immunol* 2016;16(10):626–638.
59. Tysnes OB, Storstein A. Epidemiology of Parkinson's disease. *J Neural Transm (Vienna)* 2017;124(8):901–905.
60. Georgiev D, Hamberg K, Hariz M, Forsgren L, Hariz GM. Gender differences in Parkinson's disease: a clinical perspective. *Acta Neurol Scand* 2017;136(6):570–584.
61. Kang JH, Irwin DJ, Chen-Plotkin AS, et al. Association of cerebrospinal fluid beta-amyloid 1-42, T-tau, P-tau181, and alpha-synuclein levels with clinical features of drug-naive patients with early Parkinson disease. *JAMA Neurol* 2013;70(10):1277–1287.
62. Hu X, Yang Y, Gong D. Changes of cerebrospinal fluid Abeta42, t-tau, and p-tau in Parkinson's disease patients with cognitive impairment relative to those with normal cognition: a meta-analysis. *Neurol Sci* 2017;38(11):1953–1961.

63. Hall S, Surova Y, Ohrfelt A, et al. Longitudinal measurements of cerebrospinal fluid biomarkers in Parkinson's disease. *Mov Disord* 2016;31(6):898–905.
64. Edison P, Ahmed I, Fan Z, et al. Microglia, amyloid, and glucose metabolism in Parkinson's disease with and without dementia. *Neuropsychopharmacology* 2013;38(6):938–949.
65. Bernatowicz P, Kowal K. Soluble CD163 modulates cytokine production by peripheral blood mononuclear cells stimulated by Dermatophagoides pteronyssinus allergens in vitro. *Adv Med Sci* 2016;61(2):249–254.
66. O'Connell GC, Tennant CS, Lucke-Wold N, et al. Monocyte-lymphocyte cross-communication via soluble CD163 directly links innate immune system activation and adaptive immune system suppression following ischemic stroke. *Sci Rep* 2017;7(1):12940.
67. Kristiansen M, Graversen JH, Jacobsen C, et al. Identification of the haemoglobin scavenger receptor. *Nature* 2001;409(6817):198–201.
68. Verbij FC, Sorvillo N, Kaijen PHP, et al. The class I scavenger receptor CD163 promotes internalization of ADAMTS13 by macrophages. *Blood Adv* 2017;1(5):293–305.
69. Timmermann M, Buck F, Sorg C, Hogger P. Interaction of soluble CD163 with activated T lymphocytes involves its association with non-muscle myosin heavy chain type A. *Immunol Cell Biol* 2004;82(5):479–487.
70. Barger SR, Gauthier NC, Krendel M. Squeezing in a meal: myosin functions in phagocytosis. *Trends Cell Biol* 2020;30(2):157–167.

Supporting Data

Additional Supporting Information may be found in the online version of this article at the publisher's web-site.